Amylin Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize potential drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The Group has two approved products, BYETTA(R) (exenatide) injection, and SYMLIN(R) (pramlintide acetate) injection, both of which were commercially launched ... More

Amylin Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize potential drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The Group has two approved products, BYETTA(R) (exenatide) injection, and SYMLIN(R) (pramlintide acetate) injection, both of which were commercially launched in the United States in 2005. BYETTA is the first and only approved medicine in a new class of compounds called incretin mimetics. SYMLIN is the first and only approved medicine in a new class of compounds called amylinomimetics. The Group has a global development and commercialization agreement for exenatide, including BYETTA and any sustained-release formulations of BYETTA, including exenatide LAR, with Eli Lilly & Company.